[Form 4] ANI Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Meredith W. Cook, Sr. VP, General Counsel & Sec. of ANI Pharmaceuticals (ANIP), reported the sale of 400 shares of the company’s common stock on 08/13/2025 at a price of $88.87 per share. After the sale, Ms. Cook beneficially owns 76,474 shares directly. The filing states the sale was executed under a Rule 10b5-1 trading plan adopted on September 17, 2024, indicating the transaction followed a prearranged instruction to sell. The Form 4 shows a single non-derivative disposition and lists Ms. Cook’s role and contact address with the issuer.

Positive

• Sale executed under a Rule 10b5-1 trading plan, indicating prearranged compliance measures
• Reporting person retains a substantial direct holding of 76,474 shares after the transaction
• No derivative transactions reported; only a single non-derivative disposition was disclosed

Negative

• Insider disposed of 400 shares, reducing direct ownership (though the amount is small)
• No additional context provided about reasons for the sale beyond the 10b5-1 plan adoption

Insights

Financial Analyst

TL;DR: Insider sold a small portion of holdings under a pre-established 10b5-1 plan; transaction is routine and not materially dilutive.

The reported sale of 400 shares at $88.87 represents a de minimis reduction relative to the remaining direct stake of 76,474 shares, suggesting limited market or governance signal. Execution under a 10b5-1 plan reduces the likelihood the trade was opportunistic. There is no indication of derivative activity or additional open-market program changes. From an investor-impact perspective, this disclosure is routine and likely neutral to valuation models.

Corporate Governance Expert

TL;DR: Use of a documented 10b5-1 plan demonstrates compliance with insider-trading controls; the sale appears consistent with governance best practices.

The Form 4 explicitly states the disposition was made pursuant to a Rule 10b5-1 trading plan adopted on September 17, 2024, which provides an affirmative defense to insider trading when properly structured. The small size of the sale (400 shares) and continuation of a substantial direct holding (76,474 shares) suggest no immediate governance concern or change in insider alignment with shareholders. No amendments or irregularities are disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cook Meredith

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SR. VP, GENERAL COUNSEL & SEC.

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		S(1)		400	D	$88.87	76,474	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2024.

Remarks:

	/s/ Meredith W. Cook	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction is reported for Meredith Cook in the ANIP Form 4?

The filing reports the sale of 400 shares of ANI Pharmaceuticals common stock executed on 08/13/2025 at $88.87 per share.

How many ANIP shares does Meredith Cook own after the reported sale?

After the reported transaction, Ms. Cook beneficially owns 76,474 shares directly.

Was the sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the sale was effected pursuant to a Rule 10b5-1 plan adopted on September 17, 2024.

Did the Form 4 report any derivative security transactions for ANIP?

No. The filing shows only a non-derivative disposition and contains no derivative securities activity.

What is Meredith Cook’s role at ANI Pharmaceuticals as listed on the form?

Ms. Cook is listed as Sr. VP, General Counsel & Sec. of ANI Pharmaceuticals.